Andreas Engert

37.0k total citations · 4 hit papers
552 papers, 20.7k citations indexed

About

Andreas Engert is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andreas Engert has authored 552 papers receiving a total of 20.7k indexed citations (citations by other indexed papers that have themselves been cited), including 402 papers in Pathology and Forensic Medicine, 204 papers in Oncology and 185 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andreas Engert's work include Lymphoma Diagnosis and Treatment (399 papers), Lung Cancer Treatments and Mutations (169 papers) and Chronic Lymphocytic Leukemia Research (100 papers). Andreas Engert is often cited by papers focused on Lymphoma Diagnosis and Treatment (399 papers), Lung Cancer Treatments and Mutations (169 papers) and Chronic Lymphocytic Leukemia Research (100 papers). Andreas Engert collaborates with scholars based in Germany, United States and Switzerland. Andreas Engert's co-authors include Volker Diehl, Peter Borchmann, Dennis A. Eichenauer, Andreas Josting, Bastian von Tresckow, H. Schulz, Julia Bohlius, Michael Fuchs, Nicole Skoetz and Thomas Elter and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Andreas Engert

529 papers receiving 20.2k citations

Hit Papers

Results of a Pivotal Phas... 1999 2026 2008 2017 2012 1999 2018 2014 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
  2. Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
    1999 516 citations H. Schulz, Volker Diehl et al. Blood profile →
  3. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
    2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →
  4. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2014 324 citations Dennis A. Eichenauer, Andreas Engert et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Andreas Engert 12.1k 9.2k 4.5k 4.1k 4.1k 552 20.7k
Jamés O. Armitage 15.9k 1.3× 12.4k 1.3× 4.5k 1.0× 6.2k 1.5× 4.0k 1.0× 487 25.6k
Fernando Cabanillas 18.1k 1.5× 12.9k 1.4× 4.5k 1.0× 7.5k 1.8× 3.8k 0.9× 470 25.9k
Anas Younes 11.6k 1.0× 10.9k 1.2× 2.6k 0.6× 5.0k 1.2× 4.0k 1.0× 529 22.1k
Richard I. Fisher 18.9k 1.6× 16.2k 1.8× 5.8k 1.3× 6.2k 1.5× 5.9k 1.4× 333 31.5k
Stephen M. Ansell 13.8k 1.1× 15.0k 1.6× 3.0k 0.7× 5.6k 1.4× 8.8k 2.1× 741 26.6k
Bertrand Coiffier 24.8k 2.0× 16.6k 1.8× 6.7k 1.5× 9.6k 2.3× 5.5k 1.3× 486 33.6k
Bruce D. Cheson 17.1k 1.4× 10.6k 1.2× 4.3k 0.9× 11.0k 2.7× 5.1k 1.2× 362 29.9k
Leo I. Gordon 8.0k 0.7× 6.6k 0.7× 1.7k 0.4× 3.0k 0.7× 2.2k 0.5× 453 15.0k
George P. Canellos 8.0k 0.7× 6.0k 0.6× 2.8k 0.6× 3.8k 0.9× 1.1k 0.3× 209 15.8k
Armando Santoro 8.8k 0.7× 17.8k 1.9× 2.4k 0.5× 2.6k 0.6× 2.5k 0.6× 924 34.7k

Countries citing papers authored by Andreas Engert

Since Specialization
Citations

This map shows the geographic impact of Andreas Engert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Engert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Engert more than expected).

Fields of papers citing papers by Andreas Engert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Engert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Engert. The network helps show where Andreas Engert may publish in the future.

Co-authorship network of co-authors of Andreas Engert

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Engert. A scholar is included among the top collaborators of Andreas Engert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Engert. Andreas Engert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bröckelmann, Paul J., Peter Herhaus, Julia Meißner, et al.. (2023). Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial. Blood. 142(Supplement 1). 1710–1710.
2.
3.
Fuchs, Michael, Carsten Kobe, Thomas Pabst, et al.. (2021). PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group. Blood. 138(Supplement 1). 2438–2438. 2 indexed citations
4.
Armand, Philippe, Andreas Engert, Anas Younes, et al.. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. Journal of Clinical Oncology. 36(14). 1428–1439. 455 indexed citations breakdown →
5.
Mueller, Horst, Peter Kaskel, Hilde Giezek, et al.. (2017). Clinical Outcomes of Patients with 3rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group. Blood. 130. 2793–2793. 1 indexed citations
6.
Engert, Andreas, Anneke Brand, Bertrand Coiffier, et al.. (2016). The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 101(2). 115–208. 46 indexed citations
7.
Tresckow, Bastian von, Franck Morschhauser, Vincent Ribrag, et al.. (2015). An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clinical Cancer Research. 21(8). 1843–1850. 94 indexed citations
8.
Hartmann, Sylvia, Dennis A. Eichenauer, Annette Plütschow, et al.. (2013). The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 122(26). 4246–4252. 112 indexed citations
9.
Sauer, Maike, Sabine Ponader, Andreas Engert, & Elke Pogge von Strandmann. (2013). The Chemokine CCL17/TARC as a Biomarker in Hodgkin Lymphoma. 25–29. 1 indexed citations
10.
Younes, Anas, Ajay K. Gopal, Scott E. Smith, et al.. (2012). Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology. 30(18). 2183–2189. 1014 indexed citations breakdown →
11.
Rothe, Achim, Stephanie Sasse, Helen Goergen, et al.. (2012). Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 120(7). 1470–1472. 60 indexed citations
12.
Monsef, Ina, et al.. (2012). Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database of Systematic Reviews. 2012(11). CD009355–CD009355. 24 indexed citations
13.
Radford, John, Andrew Davies, Martin J.S. Dyer, et al.. (2010). Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. British Journal of Haematology. 149. 2–3. 1 indexed citations
14.
Engert, Andreas, Volker Diehl, Jeremy Franklin, et al.. (2009). Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study. Journal of Clinical Oncology. 27(27). 4548–4554. 303 indexed citations
15.
Brillant, Corinne, Guido Schwarzer, Julia Bohlius, et al.. (2009). HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT IN FIRST LINE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA: RESULTS OF AN INDIVIDUAL PATIENT DATA META-ANALYSIS. IRIS Research product catalog (Sapienza University of Rome). 1 indexed citations
16.
Simhadri, Venkateswara R., Venkateswara R. Simhadri, Katrin S. Reiners, et al.. (2008). Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function. PLoS ONE. 3(10). e3377–e3377. 217 indexed citations
17.
18.
Eich, Hans‐Theodor, Uwe Haverkamp, Andreas Engert, et al.. (2004). Biophysical analysis of acute toxicity of radiotherapy in Hodgkin’s lymphoma — a comparison between extended field and involved field radiotherapy based on the data of the german hodgkin study group (GHSG). International Journal of Radiation Oncology*Biology*Physics. 60(1). S219–S219.
19.
Reiser, Marcel, Stefan Barth, Peter Borchmann, et al.. (2002). Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Annals of Hematology. 81(5). 258–266. 15 indexed citations
20.
Engert, Andreas, et al.. (1996). Current clinical trials in Hodgkin's disease. Annals of Oncology. 7. S109–S113. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jamés O. Armitage Breakdown of academic impact, for papers by Fernando Cabanillas Breakdown of academic impact, for papers by Anas Younes Breakdown of academic impact, for papers by Richard I. Fisher Breakdown of academic impact, for papers by Stephen M. Ansell Breakdown of academic impact, for papers by Bertrand Coiffier Breakdown of academic impact, for papers by Bruce D. Cheson Breakdown of academic impact, for papers by Leo I. Gordon Breakdown of academic impact, for papers by George P. Canellos Breakdown of academic impact, for papers by Armando Santoro
Rankless by CCL
2026